ES2856210T3 - Dosificación intermitente de inhibidor de mdm2 - Google Patents

Dosificación intermitente de inhibidor de mdm2 Download PDF

Info

Publication number
ES2856210T3
ES2856210T3 ES15733926T ES15733926T ES2856210T3 ES 2856210 T3 ES2856210 T3 ES 2856210T3 ES 15733926 T ES15733926 T ES 15733926T ES 15733926 T ES15733926 T ES 15733926T ES 2856210 T3 ES2856210 T3 ES 2856210T3
Authority
ES
Spain
Prior art keywords
methyl
mdm2i
treatment
chlorophenyl
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15733926T
Other languages
English (en)
Spanish (es)
Inventor
Stephane Ferretti
Sebastien Jeay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53510950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2856210(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2856210T3 publication Critical patent/ES2856210T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES15733926T 2014-06-26 2015-06-25 Dosificación intermitente de inhibidor de mdm2 Active ES2856210T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462017406P 2014-06-26 2014-06-26
PCT/IB2015/054792 WO2015198266A1 (en) 2014-06-26 2015-06-25 Intermittent dosing of mdm2 inhibitor

Publications (1)

Publication Number Publication Date
ES2856210T3 true ES2856210T3 (es) 2021-09-27

Family

ID=53510950

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15733926T Active ES2856210T3 (es) 2014-06-26 2015-06-25 Dosificación intermitente de inhibidor de mdm2

Country Status (18)

Country Link
US (6) US20170196866A1 (enExample)
EP (1) EP3160463B1 (enExample)
JP (1) JP6728072B2 (enExample)
KR (3) KR20220151027A (enExample)
CN (2) CN115569197A (enExample)
AU (1) AU2015278765B2 (enExample)
BR (1) BR112016029750A2 (enExample)
CA (1) CA2953079C (enExample)
CL (1) CL2016003295A1 (enExample)
ES (1) ES2856210T3 (enExample)
IL (1) IL249138B (enExample)
MX (1) MX2016017075A (enExample)
PH (1) PH12016502556A1 (enExample)
RU (1) RU2695228C2 (enExample)
SG (1) SG11201609853VA (enExample)
TN (1) TN2016000522A1 (enExample)
TW (1) TW201613576A (enExample)
WO (1) WO2015198266A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
JP2018503595A (ja) 2014-09-24 2018-02-08 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ペプチド模倣大環状分子およびその製剤
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
PL3541387T3 (pl) * 2016-11-15 2021-10-25 Novartis Ag Dawka i schemat dla inhibitorów interakcji hdm2-p53
KR20190129889A (ko) * 2017-03-31 2019-11-20 노파르티스 아게 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법
US11639355B2 (en) 2018-03-12 2023-05-02 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Substituted pyrrolo[3,4-d]imidazoles as MDM2-p53 inhibitors
WO2019180576A1 (en) 2018-03-20 2019-09-26 Novartis Ag Pharmaceutical combinations
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
US12268681B2 (en) 2018-05-25 2025-04-08 Kartos Therapeutics, Inc. Methods of treating myeloproliferative neoplasms
US20210386763A1 (en) 2018-12-20 2021-12-16 Novartis Ag Pharmaceutical combinations
BR112022004225A2 (pt) 2019-09-16 2022-05-31 Novartis Ag Uso de um inibidor de mdm2 para o tratamento de mielofibrose

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US20030139373A1 (en) 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
AU2006216780B8 (en) 2005-02-22 2010-04-22 The Regents Of The University Of Michigan Small molecule inhibitors of MDM2 and uses thereof
CN102770182B (zh) * 2009-12-22 2014-10-29 诺华股份有限公司 被取代的异喹啉酮类和喹唑酮类
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
EP2361667B1 (en) 2010-02-25 2015-04-01 Alstom Technology Ltd A wet scrubber and a method of cleaning a process gas
PE20140408A1 (es) * 2010-11-12 2014-04-10 Univ Michigan Derivados espiro-oxindol como antagonistas de mdm2
CN103261229A (zh) * 2010-12-16 2013-08-21 罗切格利卡特公司 无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法
CA2843951C (en) 2011-08-11 2019-08-06 Wout WOUTERS Use of estetrol as emergency contraceptive
US9062071B2 (en) 2011-12-21 2015-06-23 Merck Sharp & Dohme Corp. Substituted piperidines as HDM2 inhibitors
UY34591A (es) 2012-01-26 2013-09-02 Novartis Ag Compuestos de imidazopirrolidinona
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
US20130245089A1 (en) 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
WO2014020502A2 (en) * 2012-07-31 2014-02-06 Novartis Ag Markers associated with human double minute 2 inhibitors
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
EP3077004B1 (en) 2013-12-05 2020-02-19 F.Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
KR102283895B1 (ko) 2013-12-23 2021-07-30 노파르티스 아게 제약 조합물
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
JP2018508569A (ja) 2015-02-06 2018-03-29 ユニティ バイオテクノロジー インコーポレイテッド 老化関連状態の治療における化合物および使用
KR20170134462A (ko) 2015-04-13 2017-12-06 다이이찌 산쿄 가부시키가이샤 Mdm2 저해제와 btk 저해제의 병용 치료법
TWI750129B (zh) 2015-08-03 2021-12-21 瑞士商諾華公司 作為血液學毒性生物標記之ｇｄｆ-１５
ES2962460T3 (es) 2015-08-28 2024-03-19 Novartis Ag Inhibidores de mdm2 y combinaciones de estos
PL3541387T3 (pl) 2016-11-15 2021-10-25 Novartis Ag Dawka i schemat dla inhibitorów interakcji hdm2-p53
RU2019119213A (ru) 2016-11-22 2020-12-24 Новартис Аг Химический способ получения производных имидазопирролидинона и их промежуточных соединений
WO2018158225A1 (en) 2017-02-28 2018-09-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a mdm2 inhibitor, uses and pharmaceutical compositions thereof
KR20190129889A (ko) 2017-03-31 2019-11-20 노파르티스 아게 혈액 종양에서 HDM2-p53 상호작용 억제제의 용량 및 요법
EP3694518A1 (en) 2017-10-12 2020-08-19 Novartis AG Combinations of mdm2 inhibitors with inhibitors of erk for treating cancers
WO2019180576A1 (en) 2018-03-20 2019-09-26 Novartis Ag Pharmaceutical combinations
CA3115716A1 (en) 2018-10-30 2020-05-07 Dana-Farber Cancer Institute, Inc. Method of treatment of p53 wt tumors
US20210386763A1 (en) 2018-12-20 2021-12-16 Novartis Ag Pharmaceutical combinations
CA3124939A1 (en) 2019-04-04 2020-10-08 Novartis Ag Siremadlin succinate

Also Published As

Publication number Publication date
JP2017519019A (ja) 2017-07-13
BR112016029750A2 (pt) 2017-08-22
JP6728072B2 (ja) 2020-07-22
RU2695228C2 (ru) 2019-07-22
CL2016003295A1 (es) 2017-07-28
US20230092181A1 (en) 2023-03-23
PH12016502556A1 (en) 2017-04-17
CA2953079A1 (en) 2015-12-30
MX2016017075A (es) 2017-05-03
US20190209561A1 (en) 2019-07-11
US20210000824A1 (en) 2021-01-07
KR20240110659A (ko) 2024-07-15
SG11201609853VA (en) 2017-01-27
AU2015278765A1 (en) 2017-01-19
RU2017102319A3 (enExample) 2019-02-12
US11419870B2 (en) 2022-08-23
US20170196866A1 (en) 2017-07-13
WO2015198266A1 (en) 2015-12-30
US20180110779A1 (en) 2018-04-26
CN115569197A (zh) 2023-01-06
TN2016000522A1 (en) 2018-04-04
TW201613576A (en) 2016-04-16
KR20170017932A (ko) 2017-02-15
EP3160463A1 (en) 2017-05-03
AU2015278765B2 (en) 2018-08-16
RU2017102319A (ru) 2018-07-26
KR102462177B1 (ko) 2022-11-04
IL249138A0 (en) 2017-01-31
US20240261284A1 (en) 2024-08-08
CA2953079C (en) 2023-05-02
CN106456635A (zh) 2017-02-22
EP3160463B1 (en) 2020-10-21
KR20220151027A (ko) 2022-11-11
US20220233530A9 (en) 2022-07-28
IL249138B (en) 2020-09-30

Similar Documents

Publication Publication Date Title
US20240261284A1 (en) Intermittent dosing of mdm2 inhibitor
US20250228861A1 (en) Cancer Treatments Using MTA-Cooperative PRMT5 Inhibitors
JP6890659B2 (ja) ＨＤＭ２−ｐ５３相互作用阻害剤の用量およびレジメン
JP6532878B2 (ja) 組合せ医薬
JP2013512882A (ja) トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
TWI873485B (zh) 用於治療癌症之方法及包含cdk2抑制劑及cdk4抑制劑之給藥方案
KR20180041677A (ko) Mdm2 억제제 및 그의 조합물
WO2013049581A1 (en) Compositions and methods for the treatment of proliferative diseases
CA2919731A1 (en) Combinations of a btk inhibitor and fluorouracil for treating cancers
WO2021175824A1 (en) Method for administration of an anti cancer agent
CN110621377A (zh) 治疗和/或预防与放射和/或化疗暴露有关的副作用的方法、组合物以及试剂盒
JP2018502863A (ja) 白血病の治療のための４−（４−フルオロ−２−メトキシフェニル）−ｎ−｛３−［（ｓ−メチルスルホンイミドイル）メチル］フェニル｝−１，３，５−トリアジン−２−アミンの使用
RU2777519C2 (ru) Применение ингибитора parp в лечении резистентного к химиотерапии рака яичников или рака молочной железы
HK1231740B (en) Intermittent dosing of mdm2 inhibitor
HK1231740A1 (en) Intermittent dosing of mdm2 inhibitor
Jiang et al. FB23‐2 and Cisplatin Synergize to Inhibit Head and Neck Squamous Cell Carcinoma by Targeting the XPF/ERCC1 Complex
WO2022191870A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene